These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 31103629)

  • 1. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
    Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
    EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels.
    Kong B; Wu W; Valkovska N; Jäger C; Hong X; Nitsche U; Friess H; Esposito I; Erkan M; Kleeff J; Michalski CW
    Sci Rep; 2015 Feb; 5():8109. PubMed ID: 25657029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping.
    Rao J; Sinn M; Pelzer U; Riess H; Oettle H; Demir IE; Friess H; Jäger C; Steiger K; Muckenhuber A
    J Pathol Clin Res; 2024 May; 10(3):e12377. PubMed ID: 38750616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
    Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
    Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
    Sun Y; Wang P; Yang W; Shan Y; Zhang Q; Wu H
    Cancer Biol Ther; 2019; 20(6):729-739. PubMed ID: 30915884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1.
    Xia R; Hu C; Ye Y; Zhang X; Li T; He R; Zheng S; Wen X; Chen R
    Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36825600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
    Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
    Liu F; Gore AJ; Wilson JL; Korc M
    PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Xiong G; Huang H; Feng M; Yang G; Zheng S; You L; Zheng L; Hu Y; Zhang T; Zhao Y
    J Exp Clin Cancer Res; 2018 Apr; 37(1):76. PubMed ID: 29615098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
    Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma.
    Shah A; Jahan R; Kisling SG; Atri P; Natarajan G; Nallasamy P; Cox JL; Macha MA; Sheikh IA; Ponnusamy MP; Kumar S; Batra SK
    Cancer Lett; 2024 Aug; 598():217097. PubMed ID: 38964729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.